Cholinesterase Inhibitors in the Management of Canine Cognitive Dysfunction: A Review on the Mechanisms of Action, Current Evidence from Experimental and Clinical Studies, and Future Directions

Canine cognitive dysfunction is a progressive, age-related neurodegenerative disorder that shares several clinical and neuropathological features with human Alzheimer’s disease, although important differences exist between the two conditions. The central mechanisms underlying the pathophysiology of canine cognitive dysfunction include the accumulation of amyloid-β plaques, cytoplasmic deposits of phosphorylated tau protein with rarely observed neurofibrillary tangles, cortical brain atrophy, and disturbances in neurotransmitters, particularly within cholinergic pathways. Compared with those in age-matched, cognitively unimpaired and young cohorts, the number of cholinergic neurons in the basal forebrain in old, cognitively impaired dogs is significantly lower. However, cholinergic deficit does not correlate directly with cortical amyloid-β load. These neurochemical and structural changes contribute to the characteristic cognitive and behavioral deficits of canine cognitive dysfunction. Cholinesterase inhibitors, which increase synaptic acetylcholine levels by inhibiting acetylcholinesterase and/or butyrylcholinesterase, have emerged as a promising pharmacological strategy. This review critically evaluates current evidence from experimental studies investigating the effects of cholinesterase inhibitors on age-associated cognitive performance in laboratory beagle dogs, as well as clinical studies involving client-owned dogs diagnosed with canine cognitive dysfunction; describes their mechanistic basis; and outlines currently available symptomatic pharmacological interventions, such as the monoamine oxidase B inhibitor selegiline (L-deprenyl), and non-pharmacological interventions, including environmental enrichment, regular exercise, diet, and nutritional supplements. Furthermore, it identifies knowledge gaps and proposes future research directions that could support the translation of cholinesterase inhibitors into effective therapeutic interventions for improving cognitive function and quality of life in aging dog populations.

Authors

Institutions

Publication Details

Journal
Animals
Published
2026-11-20
DOI
https://doi.org/10.3390/ani16223692
Primary Topic
Cholinesterase and Neurodegenerative Diseases
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Cholinesterase Inhibitors in the Management of Canine Cognitive Dysfunction: A Review on the Mechanisms of Action, Current Evidence from Experimental and Clinical Studies, and Future Directions

Tomaž Trobec
1 links
Animals
Cholinesterase and Neurodegenerative Diseases
article

Cholinesterase Inhibitors in the Management of Canine Cognitive Dysfunction: A Review on the Mechanisms of Action, Current Evidence from Experimental and Clinical Studies, and Future Directions

Tomaž Trobec
article en

Abstract

Canine cognitive dysfunction is a progressive, age-related neurodegenerative disorder that shares several clinical and neuropathological features with human Alzheimer’s disease, although important differences exist between the two conditions. The central mechanisms underlying the pathophysiology of canine cognitive dysfunction include the accumulation of amyloid-β plaques, cytoplasmic deposits of phosphorylated tau protein with rarely observed neurofibrillary tangles, cortical brain atrophy, and disturbances in neurotransmitters, particularly within cholinergic pathways. Compared with those in age-matched, cognitively unimpaired and young cohorts, the number of cholinergic neurons in the basal forebrain in old, cognitively impaired dogs is significantly lower. However, cholinergic deficit does not correlate directly with cortical amyloid-β load. These neurochemical and structural changes contribute to the characteristic cognitive and behavioral deficits of canine cognitive dysfunction. Cholinesterase inhibitors, which increase synaptic acetylcholine levels by inhibiting acetylcholinesterase and/or butyrylcholinesterase, have emerged as a promising pharmacological strategy. This review critically evaluates current evidence from experimental studies investigating the effects of cholinesterase inhibitors on age-associated cognitive performance in laboratory beagle dogs, as well as clinical studies involving client-owned dogs diagnosed with canine cognitive dysfunction; describes their mechanistic basis; and outlines currently available symptomatic pharmacological interventions, such as the monoamine oxidase B inhibitor selegiline (L-deprenyl), and non-pharmacological interventions, including environmental enrichment, regular exercise, diet, and nutritional supplements. Furthermore, it identifies knowledge gaps and proposes future research directions that could support the translation of cholinesterase inhibitors into effective therapeutic interventions for improving cognitive function and quality of life in aging dog populations.

AnimalsVol. 16(22)
University of Ljubljana (SI)
Javna Agencija za Raziskovalno Dejavnost RS
Good health and well-being
Cholinesterase and Neurodegenerative Diseases
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon